A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia
Latest Information Update: 04 Mar 2025
At a glance
- Drugs SAR 442501 (Primary)
- Indications Achondroplasia
- Focus Adverse reactions
- Acronyms upreACH-2
- Sponsors Sanofi
Most Recent Events
- 25 Feb 2025 Status changed from active, no longer recruiting to discontinued, as per the sponsor's decision, not related to safety concerns.
- 27 Jan 2025 Planned End Date changed from 2 Dec 2027 to 12 Feb 2025.
- 27 Jan 2025 Planned primary completion date changed from 2 Dec 2027 to 12 Feb 2025.